NCT04446442 Cerebellar tDCS in Children With Autism Spectrum Disorder
| NCT ID | NCT04446442 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Texas Southwestern Medical Center |
| Condition | Autism Spectrum Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2019-06-04 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2019-06-04 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to investigate whether tDCS to the cerebellum (specifically, the right crus I/II area of the cerebellum) of children and young adults with autism spectrum disorders (ASD) is safe and to examine its effects on some of the symptoms of ASD, such as repetitive behaviors and hyperactivity.
Eligibility Criteria
Inclusion Criteria: * 4-17 years old * Diagnosed with ASD and ADOS-2 * IQ Score no less than 70 (1.5 Standard Deviations below the mean) * Language Level (Speech consists of, at minimum, flexible, spontaneous, simple, sentences) Exclusion Criteria: * Brain implants, metal implants, pacemakers, or biomedical devices * Diagnosis of epilepsy * Hearing or visual impairments * History of brain injury * Known brain abnormalities not associated with ASD
Contact & Investigator
Peter Tsai, MD, PhD
PRINCIPAL INVESTIGATOR
University of Texas Southwestern Medical Center
Frequently Asked Questions
Who can join the NCT04446442 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, up to 17 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04446442 currently recruiting?
Yes, NCT04446442 is actively recruiting participants. Contact the research team at peter.tsai@utsouthwestern.edu for enrollment information.
Where is the NCT04446442 trial being conducted?
This trial is being conducted at Dallas, United States, Dallas, United States.
Who is sponsoring the NCT04446442 clinical trial?
NCT04446442 is sponsored by University of Texas Southwestern Medical Center. The principal investigator is Peter Tsai, MD, PhD at University of Texas Southwestern Medical Center. The trial plans to enroll 60 participants.